Chad Landmon, Hatch-Waxman & Biologics Chair, joins a panel of experts to discuss the unanimous decision in the case that challenged the FDA’s ability to approve the abortion medication mifepristone, as well as the cases that challenged the Chevron doctrine, where courts deferred to an agency’s interpretation of an ambiguous statute.